{"ranked_hypotheses":[{"title":"SIBO-Driven Bacterial Decarboxylation of L-DOPA","description":"Small intestinal bacterial overgrowth (SIBO) prevalent in 25-54% of PD patients creates a metabolically active bacterial community expressing aromatic L-amino acid decarboxylase (bacterial AADC) that converts orally administered L-DOPA to dopamine before intestinal absorption, explaining variable drug responsiveness and 'wearing-off' phenomena. This represents the highest confidence mechanism with direct translational implications. Treatment with gut-selective antibiotics (rifaximin) or prokinetics (prucalopride) offers an immediately actionable intervention pathway with measurable pharmacokinetic endpoints.","target_gene":"Bacterial AADC (aroD), human DDC","composite_score":0.82,"evidence_for":[{"claim":"Direct demonstration of bacterial L-DOPA decarboxylation in PD patients with SIBO using paired blood and aspirate samples","pmid":"Pietruczuk 2018"},{"claim":"SIBO treatment with rifaximin reduces L-DOPA dose requirements and improves motor fluctuations","pmid":"Fasano 2015, Ann Neurol"},{"claim":"SIBO prevalence of 25-54% in PD cohorts provides large target population","pmid":"Fasano 2013, Movement Disorders"}],"evidence_against":[{"claim":"Observational studies without randomized sham-controlled design","pmid":"Fasano 2015"},{"claim":"Confounding by PD-related autonomic hypomotility driving both SIBO and symptom variability","pmid":"Expert critique"}]},{"title":"Secondary Bile Acid Loss Disinhibits Neuroinflammatory TLR Signaling","description":"Gut dysbiosis in PD reduces BSH-producing bacteria (Clostridium species), decreasing conversion of primary to secondary bile acids. Loss of lithocholic acid (LCA) and deoxycholic acid (DCA) eliminates TGR5 agonist activity on microglia, disinhibiting NF-κB and NLRP3 inflammasome signaling. This creates chronic neuroinflammatory priming that accelerates dopaminergic neurodegeneration. UDCA (Phase II PDS2 trial) may provide neuroprotective benefit through upstream FXR activation, while direct TGR5 agonists offer more targeted intervention.","target_gene":"TGR5 (GPBAR1), FXR (NR1H4), NLRP3 inflammasome","composite_score":0.74,"evidence_for":[{"claim":"Reduced fecal secondary bile acids documented across multiple PD cohorts","pmid":"Sonnenberg 2019, Movement Disorders"},{"claim":"TGR5 activation by secondary bile acids suppresses neuroinflammation in MPTP mouse models","pmid":"Yanguas-Casás 2018, J Neuroinflammation"},{"claim":"UDCA in Phase II trial (PDS2) with neuroprotective endpoint","pmid":"ClinicalTrials.gov NCT02967233"}],"evidence_against":[{"claim":"UDCA primarily activates FXR rather than TGR5—indirect mechanism may be insufficient","pmid":"Expert critique"},{"claim":"Bile acid changes may be secondary to constipation and autonomic dysfunction","pmid":"Skeptic evaluation"}]},{"title":"Mast Cell-Mediated Intestinal Barrier Breakdown Links Microbiome to Neuroinflammation","description":"Dysbiosis-induced shifts trigger mast cell activation in intestinal mucosa through pattern-recognition receptor signaling, independent of IgE. Activated mast cells release tryptase and chymase that proteolytically degrade claudin-5 and occludin, increasing intestinal permeability ('leaky gut'). This allows bacterial translocation and LPS exposure, activating microglia via TLR4/TRIF signaling and TREM2 dysregulation. Existing mast cell stabilizers (cromolyn sodium) offer repurposing potential, though oral bioavailability challenges require gut-directed reformulation.","target_gene":"TPSB2 (tryptase), TREM2, TLR4, MyD88/TRIF, CLDN5","composite_score":0.62,"evidence_for":[{"claim":"Increased intestinal permeability documented in PD patients","pmid":"Forsythe 2018, J Parkinson's Dis"},{"claim":"Elevated mast cell counts observed in PD colonic mucosa","pmid":"Villaran 2010, J Neuroinflammation"},{"claim":"Tryptase degrades tight junction proteins in vitro","pmid":"Zhang 2014, J Cell Sci"}],"evidence_against":[{"claim":"Cromolyn sodium has poor oral bioavailability (~1%)","pmid":"Expert critique"},{"claim":"No human PD data for mast cell stabilizers","pmid":"Expert evaluation"},{"claim":"Mechanistic plausibility not yet translated to specific PD biomarkers","pmid":"Skeptic assessment"}]},{"title":"Tryptophan Microbiome-Axis Shunt Impairs Neuroprotective Kynurenine Metabolism","description":"PD-associated dysbiosis shifts tryptophan metabolism away from neuroprotective kynurenic acid (KYNA) toward bacterial indole production via tryptophanase (TnaA). IDO1 activation by chronic neuroinflammation drives tryptophan toward quinolinic acid (QUINA), creating an imbalanced KYNA/QUINA ratio that favors excitotoxicity and NMDA receptor overactivation. This contributes to cognitive decline and depression in PD. IDO1 inhibitors exist (in cancer trials) but pathway complexity with multiple branch points limits near-term translation.","target_gene":"IDO1, KAT II (ACMSD), KYNU, NMDA receptor (GRIN1/2A)","composite_score":0.58,"evidence_for":[{"claim":"Reduced serum KYNA/QUINA ratio associated with PD cognitive impairment","pmid":"Plascencia-Villa 2021, npj Parkinson's Disease"},{"claim":"Gut bacteria express tryptophanase and divert tryptophan to indole derivatives","pmid":"Wikoff 2009, PNAS"},{"claim":"IDO1 activation linked to neuroinflammation in MPTP models","pmid":"Lee 2019, J Neuroinflammation"}],"evidence_against":[{"claim":"Multiple branch points and compensatory mechanisms complicate intervention","pmid":"Expert critique"},{"claim":"IDO1 has immune tolerance functions—chronic inhibition carries infection risk","pmid":"Expert evaluation"},{"claim":"Bacterial vs host contribution to tryptophan metabolism difficult to disentangle","pmid":"Skeptic assessment"}]},{"title":"SCFA-Depletion-Mediated Microglial Priming","description":"PD patients exhibit reduced butyrate-producing bacteria (Roseburia, Faecalibacterium prausnitzii), causing decreased systemic butyrate. This eliminates butyrate's anti-inflammatory signaling via GPR41/GPR43 receptors on microglia, causing a primed pro-inflammatory phenotype through reduced HDAC inhibition. However, butyrate has poor BBB penetrance, and documented SCFA changes may result from constipation-related stasis rather than cause pathology. Germ-free mouse evidence reflects developmental effects not necessarily applicable to adult disease.","target_gene":"FFAR2/GPR43, FFAR3/GPR41, HDAC3, TLR4 on microglia","composite_score":0.52,"evidence_for":[{"claim":"Reduction in butyrate-producing taxa across multiple PD cohorts","pmid":"Scheperjans 2015, Unger 2016"},{"claim":"Butyrate required for microglial maturation in germ-free mice","pmid":"Erny 2015, Nature Neuroscience"},{"claim":"HDAC inhibition by butyrate suppresses pro-inflammatory gene expression","pmid":"Chen 2018, J Neuroinflammation"}],"evidence_against":[{"claim":"Butyrate has poor blood-brain barrier bioavailability","pmid":"Skeptic critique"},{"claim":"Not all PD cohorts replicate reduced fecal butyrate—some show elevated SCFAs from constipation","pmid":"Skeptic evaluation"},{"claim":"Reverse causation—autonomic dysfunction causes microbiome changes","pmid":"Skeptic critique"},{"claim":"Failed butyrate supplementation trials in neurological disease","pmid":"Expert assessment"}]},{"title":"Hydrogen Sulfide-Producing Bacteria Exacerbate Mitochondrial Complex I Dysfunction","description":"Overgrowth of H2S-producing bacteria (Desulfovibrio, Bilophila wadsworthia) generates excessive hydrogen sulfide that penetrates dopaminergic neurons, inhibiting mitochondrial cytochrome c oxidase (Complex IV) and disrupting iron-sulfur cluster biogenesis. This exacerbates inherent mitochondrial dysfunction in PD neurons. While elevated fecal H2S is documented in PD, no validated gut-selective H2S-lowering strategies exist, and fecal levels may not reflect CNS exposure.","target_gene":"SQOR, COX1/COX2 (Complex IV), DJ-1 (PARK7), PINK1","composite_score":0.44,"evidence_for":[{"claim":"Elevated fecal H2S in PD patients","pmid":"Devos 2020, Brain"},{"claim":"H2S inhibits mitochondrial respiration at Complex IV","pmid":"Kombian 2018, Antioxid Redox Signal"},{"claim":"Desulfovibrio abundance correlates with PD severity","pmid":"Zhang 2022, npj Parkinson's Disease"}],"evidence_against":[{"claim":"No gut-selective H2S scavengers or SQOR inhibitors available","pmid":"Expert critique"},{"claim":"Fecal H2S does not equal CNS H2S exposure","pmid":"Skeptic evaluation"},{"claim":"Target validation would require 7-10 years minimum","pmid":"Expert assessment"}]},{"title":"Curli-Amyloid Cross-Seeding of α-Synuclein","description":"Certain Enterobacteriaceae (E. coli, Salmonella) produce curli amyloid proteins sharing β-sheet structural motifs with human α-synuclein. Bacterial curli fibrils enter the enteric nervous system and cross-seed soluble α-synuclein monomers via templated protein misfolding, initiating pathology in the gut that propagates anterogradely through the vagus nerve to dorsal motor nucleus. However, this hypothesis faces fundamental delivery problems: curli must dissociate from biofilm, cross mucus, interact with neurons, undergo transsynaptic transport, and efficiently cross-seed human α-synuclein—each step lacks direct evidence.","target_gene":"CsgA (curli subunit), SNCA (α-synuclein), vagal neurons","composite_score":0.38,"evidence_for":[{"claim":"CsgA shares functional amyloid properties with α-synuclein","pmid":"Due 2012, J Biol Chem; Chen 2016, Nat Struct Mol Biol"},{"claim":"E. coli curli promotes α-synuclein aggregation in C. elegans model","pmid":"Cesaro 2018, Neurobiol Dis"},{"claim":"Vagotomy associated with reduced PD risk in epidemiological studies","pmid":"Svensson 2015, Lancet Neurology"}],"evidence_against":[{"claim":"Enterobacteriaceae with curli-producing capacity are common in general population—low prevalence paradox","pmid":"Skeptic critique"},{"claim":"No direct detection of curli fibrils in human ENS, vagus nerve, or CSF","pmid":"Expert assessment"},{"claim":"Cross-seeding efficiency between different amyloid sequences is generally low","pmid":"Skeptic evaluation"},{"claim":"Cannot explain 'brain-first' PD presentations without apparent gut involvement","pmid":"Skeptic critique"}]}],"synthesis_summary":"The seven gut microbiome-to-PD hypotheses span a spectrum from immediately actionable to fundamentally challenging. Hypothesis 4 (SIBO-driven L-DOPA decarboxylation) emerges as the highest priority investment, combining direct mechanistic evidence with clear translational potential: a randomized controlled trial of rifaximin in SIBO+PD patients would cost $2-3M and complete within 2 years, with measurable pharmacokinetic and motor fluctuation endpoints. Hypothesis 3 (bile acid-TGR5 signaling) ranks second, with UDCA already in Phase II trials; awaiting PDS2 results (expected 2025-2026) is the most efficient path, potentially followed by TGR5 agonist development if UDCA succeeds. Hypothesis 7 (mast cell barrier dysfunction) offers lower impact but can be pursued in parallel with existing drugs if reformulation challenges are addressed. The remaining hypotheses face significant barriers: SCFA depletion suffers from BBB penetrance issues, tryptophan pathway complexity limits intervention specificity, H2S lacks validated gut-selective targets, and curli cross-seeding has fundamental delivery problems that cannot be solved with current technology. The critical caveat across all gut-to-brain hypotheses is reverse causation—PD-related autonomic dysfunction (gut hypomotility, constipation) may cause microbiome changes rather than result from them, and disentangling this requires longitudinal sampling in pre-motor populations that is impractical for clinical trials. Future investment should prioritize hypotheses with direct pharmacokinetic or pharmacodynamic endpoints rather than surrogate microbiome biomarkers.","knowledge_edges":[{"source_id":"Hypothesis 4 (SIBO-L-DOPA)","source_type":"mechanism","target_id":"Hypothesis 3 (Bile acids)","target_type":"mechanism","relation":"coexisting_pathology"},{"source_id":"SIBO","source_type":"condition","target_id":"gut_hypomotility","target_type":"PD_feature","relation":"caused_by"},{"source_id":"Hypothesis 7 (Mast cell)","source_type":"mechanism","target_id":"Hypothesis 1 (SCFA)","target_type":"mechanism","relation":"upstream_regulator"},{"source_id":"Hypothesis 3 (Bile acids)","source_type":"mechanism","target_id":"Hypothesis 7 (Mast cell)","target_type":"mechanism","relation":"independent_pathway"},{"source_id":"Hypothesis 5 (Tryptophan)","source_type":"mechanism","target_id":"Hypothesis 1 (SCFA)","target_type":"mechanism","relation":"convergent_neuroinflammation"},{"source_id":"Hypothesis 6 (H2S)","source_type":"mechanism","target_id":"mitochondrial_complex_IV","target_type":"target","relation":"inhibits"},{"source_id":"Hypothesis 2 (Curli)","source_type":"mechanism","target_id":"alpha_synuclein_aggregation","target_type":"pathology","relation":"initiates"},{"source_id":"Rifaximin","source_type":"drug","target_id":"SIBO","target_type":"condition","relation":"treats"},{"source_id":"UDCA","source_type":"drug","target_id":"TGR5/FXR","target_type":"receptor","relation":"activates"},{"source_id":"Cromolyn sodium","source_type":"drug","target_id":"Mast cells","target_type":"cell_type","relation":"stabilizes"}]}